Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce to help extend its cash into second-quarter 2026, ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

These seven blue-chip dividend stocks provide investors a steady stream of passive income and offer promising total return.

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

LivaNova PLC today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14.

Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in ...

By contrast, the most common Cobenfy side effects in clinical trials were somewhat mild by comparison: nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, increased ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of some unusual options trading on Thursday. Investors purchased 296,826 call options on the stock. This represents an increase of 866% ...